Get the Stockscreener App
49.80
8.21%
3.78
Vera Therapeutics Inc stock is traded at $49.80, with a volume of 1.38M.
It is up +8.21% in the last 24 hours and up +60.23% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$46.02
Open:
$45.93
24h Volume:
1.38M
Relative Volume:
0.89
Market Cap:
$3.18B
Revenue:
-
Net Income/Loss:
$-218.28M
P/E Ratio:
-13.91
EPS:
-3.5803
Net Cash Flow:
$-186.55M
1W Performance:
+10.91%
1M Performance:
+60.23%
6M Performance:
+121.14%
1Y Performance:
+10.40%
1-Day Range:
$45.45
$50.16
1-Week Range:
$40.38
$50.16
52-Week Range:
$18.53
$50.16
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
49.80 | 2.94B | 0 | -218.28M | -186.55M | -3.5803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Initiated | BofA Securities | Buy |
| Aug-04-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-05-25 | Resumed | H.C. Wainwright | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Vera Therapeutics (NASDAQ:VERA) Trading Up 5.3%Still a Buy? - MarketBeat
Vera Therapeutics Sees Optimism as Analysts Boost Price Targets - timothysykes.com
Vera Therapeutics (NASDAQ:VERA) Hits New 12-Month HighHere's Why - MarketBeat
Avoiding Lag: Real-Time Signals in (VERA) Movement - news.stocktradersdaily.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Wedbush Maintains Vera Therapeutics (VERA) Neutral Recommendation - Nasdaq
Vera Therapeutics stock hits 52-week high at 47.12 USD By Investing.com - Investing.com Canada
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets - ts2.tech
Wedbush Raises Price Target on Vera Therapeutics to $33 From $23, Keeps Neutral Rating - marketscreener.com
Vera Therapeutics, Inc. $VERA Shares Bought by Jump Financial LLC - MarketBeat
Vera Therapeutics Completes Successful Stock Offering - TipRanks
Vera Therapeutics Announces Follow-On Public Offering - TradingView — Track All Markets
188,422 Shares in Vera Therapeutics, Inc. $VERA Acquired by Norges Bank - MarketBeat
Vera Therapeutics Prices $261 Million Public Offering - marketscreener.com
Vera Therapeutics prices public offering at $42.50 per share By Investing.com - Investing.com Nigeria
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - markets.businessinsider.com
Vera Therapeutics prices public offering at $42.50 per share - Investing.com
Vera Therapeutics prices public offering of Class A Common Stock at $42.50 per share - marketscreener.com
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock at $42.50 per Share - Quiver Quantitative
Polycythemia Vera Clinical Trial Pipeline Shows Potential with Active Contributions from 8+ Key Companies | DelveInsight - The Globe and Mail
Vera Therapeutics (NASDAQ:VERA) Shares Gap DownWhat's Next? - MarketBeat
Vera Therapeutics announces $200M public offering - MSN
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - markets.businessinsider.com
Evercore ISI Group Maintains Vera Therapeutics (VERA) Outperform Recommendation - Nasdaq
Vera Therapeutics Plans Offering of Common Shares - marketscreener.com
Vera Therapeutics (VERA) proposes $200M Class A share sale with 15% underwriter option - Stock Titan
Evercore ISI Group Raises Price Target for Vera Therapeutics (VE - GuruFocus
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bollard Group LLC Takes $1.51 Million Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Assessing Vera Therapeutics (VERA) Valuation After Adding Industry Veteran James R. Meyers to Its Board - Sahm
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $73.00 - MarketBeat
Vera Therapeutics, Inc. $VERA Shares Sold by Affinity Asset Advisors LLC - MarketBeat
Vera Therapeutics Inc. (VERA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Vera Therapeutics Stock is Climbing Higher - TipRanks
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $73 - 富途牛牛
Schroder Investment Management Group Reduces Stock Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics stock price target raised to $73 from $60 at TD Cowen - Investing.com UK
Vera Therapeutics exec Turner sells $400k in shares By Investing.com - Investing.com Canada
Vera Therapeutics exec Turner sells $400k in shares - Investing.com
Vera Therapeutics Executive Sells 10,000 Shares - TradingView
Will Vera Therapeutics Inc. stock reach Wall Street targets2025 Institutional Moves & Consistent Growth Stock Picks - Newser
Why Vera Therapeutics Inc. stock is trending among retail tradersMarket Volume Summary & Short-Term Trading Opportunity Alerts - Newser
Is Vera Therapeutics’ Recent 69% Surge Justified by Its Valuation in 2025? - Yahoo Finance
Vera Therapeutics rises 19.2% - MSN
Vera Therapeutics Stock Soars: Time to Buy? - StocksToTrade
Vera Therapeutics (VERA): Reassessing Valuation After Positive Phase 3 IgAN Data and Accelerated FDA Path - Yahoo Finance
Is Vera Therapeutics (VERA) Quietly Recasting Its Commercial Strategy With the Meyers Board Appointment? - Yahoo Finance
Vera Therapeutics (NASDAQ:VERA) Stock Price Up 6.7%Here's What Happened - MarketBeat
Vera Therapeutics, Inc. (VERA): A Top Gainer with Promising FDA Approvals - Meyka
Vera Therapeutics: Stock Rises As IgAN Approval Chances IncreaseI'm On Sidelines (VERA) - Seeking Alpha
American Century Companies Inc. Raises Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vera Therapeutics Inc Stock (VERA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Turner William D. | Chief Regulatory Officer |
Dec 08 '25 |
Sale |
45.31 |
10,000 |
453,053 |
22,500 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):